A5024898478- Cancer Immunotherapy and Biomarkers
- Single-cell and spatial transcriptomics
- Immune cells in cancer
- Cell Image Analysis Techniques
- Radiomics and Machine Learning in Medical Imaging
- Immunotherapy and Immune Responses
- Molecular Biology Techniques and Applications
- Peptidase Inhibition and Analysis
- Bladder and Urothelial Cancer Treatments
- RNA modifications and cancer
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Cancer Cells and Metastasis
- AI in cancer detection
- Prostate Cancer Diagnosis and Treatment
- Ferroptosis and cancer prognosis
- Prostate Cancer Treatment and Research
- Urinary and Genital Oncology Studies
University Medical Center Hamburg-Eppendorf
2022-2024
Universität Hamburg
2022-2024
Abstract Microsatellite instability is a strong predictor of response to immune checkpoint therapy and patient outcome in colorectal cancer. Although enrichment distinct T‐cell subpopulations has been determined impact the outcome, little known about underlying changes composition tumor microenvironment. To assess density, composition, degree functional marker expression, spatial interplay subpopulations, 79 microsatellite instable (MSI) 1,045 stable (MSS) cancers were analyzed. A tissue...
Quantity and the spatial relationship of specific immune cell types can provide prognostic information in bladder cancer. The objective study was to characterize interplay role different subpopulations
Abstract Multiplex fluorescence IHC (mfIHC) approaches were yet either limited to six markers or a small tissue size that hampers translational studies on large microarray cohorts. Here we have developed BLEACH&STAIN mfIHC method enabled the simultaneous analysis of 15 biomarkers (PD-L1, PD-1, CTLA-4, panCK, CD68, CD163, CD11c, iNOS, CD3, CD8, CD4, FOXP3, CD20, Ki67, and CD31) in 3,098 tumor samples from 44 different carcinoma entities within one week. To facilitate automated immune...
Trophoblast cell surface antigen 2 (TROP2; EpCAM2) is a transmembrane glycoprotein which closely related to EpCAM (EpCAM; EpCAM1). Both proteins share partial overlapping functions in epithelial development and expression but have not been comparatively analyzed together bladder carcinomas. TROP2 constitutes the target for antibody-drug conjugate Sacituzumab govitecan (SG; TrodelvyTM) has approved treatment of metastatic urothelial carcinoma by United States Food Drug administration (FDA)...
<div>Abstract<p>Multiplex fluorescence immunohistochemistry (mfIHC) approaches were yet either limited to 6 markers or a small tissue size that hampers translational studies on large microarray cohorts. Here we have developed BLEACH&STAIN mfIHC method enabled the simultaneous analysis of 15 biomarkers (PD-L1, PD-1, CTLA-4, panCK, CD68, CD163, CD11c, iNOS, CD3, CD8, CD4, FOXP3, CD20, Ki67, CD31) in 3098 tumor samples from 44 different carcinoma entities within one week. To...
Prognostic markers in routine clinical management of breast cancer are often assessed using RNA-based multi-gene panels that depend on fluctuating tumor purity. Multiplex fluorescence immunohistochemistry (mfIHC) holds the potential for an improved risk assessment. To enable automated prognosis marker detection (i.e., progesterone receptor [PR], estrogen [ER], androgen [AR], GATA3, TROP2, HER2, PD-L1, Ki67, TOP2A), a framework identification was developed and validated involving thirteen...
<div>Abstract<p>Multiplex fluorescence IHC (mfIHC) approaches were yet either limited to six markers or a small tissue size that hampers translational studies on large microarray cohorts. Here we have developed BLEACH&STAIN mfIHC method enabled the simultaneous analysis of 15 biomarkers (PD-L1, PD-1, CTLA-4, panCK, CD68, CD163, CD11c, iNOS, CD3, CD8, CD4, FOXP3, CD20, Ki67, and CD31) in 3,098 tumor samples from 44 different carcinoma entities within one week. To facilitate...
<div>Abstract<p>Multiplex fluorescence IHC (mfIHC) approaches were yet either limited to six markers or a small tissue size that hampers translational studies on large microarray cohorts. Here we have developed BLEACH&STAIN mfIHC method enabled the simultaneous analysis of 15 biomarkers (PD-L1, PD-1, CTLA-4, panCK, CD68, CD163, CD11c, iNOS, CD3, CD8, CD4, FOXP3, CD20, Ki67, and CD31) in 3,098 tumor samples from 44 different carcinoma entities within one week. To facilitate...
Abstract Background: A combination of different immune-checkpoint-inhibitors (ICIs) have shown remarkable success in several tumor entities. However, the likelihood positive response to ICIs is poor most entities and recent evidence suggests that quantity expression level immune checkpoints such as TIM3, CTLA-4, PD-1 infiltrating lymphocytes (TILs) influences checkpoint inhibitors. Design: To assess density spatial interplay 42 expressing leukocyte subpopulations 6031 samples from 49...
Abstract Background: The composition and functional state of T-cell subpopulations can highly impact patient’s outcome response to immune checkpoint therapy. However, only little is known about the spatial interplay most rare subpopulations. Design: To assess density, composition, degree expression, in 5989 tumor samples from more than 100 entities, two different types tissue microarrays (0.6 mm 4 diameter) were stained with antibodies directed against CD3, CD4, CD8, FOXP3, T-bet, GATA3,...
<div>Abstract<p>Multiplex fluorescence immunohistochemistry (mfIHC) approaches were yet either limited to 6 markers or a small tissue size that hampers translational studies on large microarray cohorts. Here we have developed BLEACH&STAIN mfIHC method enabled the simultaneous analysis of 15 biomarkers (PD-L1, PD-1, CTLA-4, panCK, CD68, CD163, CD11c, iNOS, CD3, CD8, CD4, FOXP3, CD20, Ki67, CD31) in 3098 tumor samples from 44 different carcinoma entities within one week. To...
Abstract An increasing number of therapy regimens using a combination different immune checkpoint inhibitors (ICIs) have shown remarkable results in several tumor entities. However, the likelihood positive response rate to combined ICIs is poor most entities and depends on parameters including microenvironment. Particularly little known about spatial orchestration interplay between expressing cells. Given that T-cell immunoglobulin mucin domain-containing protein 3 (TIM3) expressed both...
Abstract The assessment of prognostic markers in routine clinical practice breast cancer is currently performed using multi gene RNA panels. However, the unknown proportion normal tissue relation to malignant can reduce predictive value such tests. Immunohistochemistry holds potential for a better tumors because tumor cells be separately analyzed. To enable automated prognosis marker detection (i.e. HER2, GATA3, progesterone receptor [PR], estrogen [ER], androgen [AR], TOP2A, Ki-67, TROP2,...
Abstract Introduction/Objective Although most prostate cancers behave in an indolent manner, a small proportion is highly aggressive. To evaluate the patient’s risk, several prognosis parameters, that can be accompanied by high interobserver variability has been established. A reproducible prognostic evaluation lacking. Methods/Case Report enable automated marker quantification, we have developed and validated framework for cancer detection comprises three different artificial intelligence...
Abstract Introduction/Objective Introduction: Prognostic markers in routine clinical practice of breast cancer are currently assessed using multi-gene panels. However, the fluctuating tumor purity can reduce predictive value such tests. Immunohistochemistry holds potential for a better risk assessment. Methods/Case Report Methods: To enable automated prognosis marker detection (i.e. HER2, GATA3, progesterone-[PR], estrogen- [ER], and androgen receptor [AR], TOP2A, Ki-67, TROP2), we have...